Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| DLL3 mAb - 01 | Lead | Solid Tumor | Small cell lung cancer |
Expression analysis of human DLL3 on CHO/Human DLL3 Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human DLL3 Stable Cell Line or negative control cell using anti-human DLL3 antibody followed by staining with PE anti-human IgG Fc Antibody.
Expression analysis of human DLL3 on HEK293/Human DLL3 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human DLL3 Stable Cell Line or negative control cell using anti-human DLL3 antibody followed by staining with PE anti-human IgG Fc antibody.
Bispecific T-cell Engager captured on Protein A Chip can bind Cynomolgus DLL3 (27-488), His Tag (Cat. No. DL3-C52H9) with an affinity constant of 1.02 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| MK-6070 | HPN-328; MK-6070 | Phase 2 Clinical | Harpoon Therapeutics | Small Cell Lung Carcinoma | Details |
| BI-764532 | BI-764532; OBT620 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Small Cell Lung Carcinoma; Neoplasms; Neuroendocrine Tumors; Carcinoma, Neuroendocrine; Glioma | Details |
| ZG006 | ZG006; ZG-006 | Phase 2 Clinical | Gensun Biopharma Inc, Suzhou Zelgen Biopharmaceuticals Co Ltd | Solid tumours; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details |
| 89Zr-DFO-SC16.56 | 89Zr-DFO-SC16.56 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Small Cell Lung Carcinoma | Details |
| ZL-1310 | ZL-1310; ZL1310; YL212 | Phase 1 Clinical | Zai Lab (Shanghai) Co Ltd, MediLink Therapeutics Co Ltd | Small Cell Lung Carcinoma; Carcinoma, Small Cell | Details |
| FZ-AD005 | FZAD005; FZ-AD005 | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours | Details |
| [89Zr]Zr-BI-764532 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg, Boehringer Ingelheim Gmbh | Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details | |
| OBT620 | OBT620 | Phase 1 Clinical | Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd | Small Cell Lung Carcinoma | Details |
| DLL3-CAR-NK cells Therapy(Tianjin Medical University Cancer Institute and Hospital) | DLL3-CAR-NK cells | Phase 1 Clinical | Tianjin Medical University Cancer Institute And Hospital | Small Cell Lung Carcinoma | Details |
| QLS-31904 | QLS31904; QLS-31904 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| LB-2102(Legend Biotechnology) | LB-2102 | Phase 1 Clinical | Small Cell Lung Carcinoma; Neuroendocrine Tumors | Details | |
| PT-217 | PT-217 | Phase 1 Clinical | Phanes Therapeutics Inc | Solid tumours; Small Cell Lung Carcinoma; Pancreatic neuroendocrine tumors (pNET); Prostatic Neoplasms; Carcinoma, Neuroendocrine | Details |
| MK-6070 | HPN-328; MK-6070 | Phase 2 Clinical | Harpoon Therapeutics | Small Cell Lung Carcinoma | Details |
| BI-764532 | BI-764532; OBT620 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Small Cell Lung Carcinoma; Neoplasms; Neuroendocrine Tumors; Carcinoma, Neuroendocrine; Glioma | Details |
| ZG006 | ZG006; ZG-006 | Phase 2 Clinical | Gensun Biopharma Inc, Suzhou Zelgen Biopharmaceuticals Co Ltd | Solid tumours; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details |
| 89Zr-DFO-SC16.56 | 89Zr-DFO-SC16.56 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Small Cell Lung Carcinoma | Details |
| ZL-1310 | ZL-1310; ZL1310; YL212 | Phase 1 Clinical | Zai Lab (Shanghai) Co Ltd, MediLink Therapeutics Co Ltd | Small Cell Lung Carcinoma; Carcinoma, Small Cell | Details |
| FZ-AD005 | FZAD005; FZ-AD005 | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours | Details |
| [89Zr]Zr-BI-764532 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg, Boehringer Ingelheim Gmbh | Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details | |
| OBT620 | OBT620 | Phase 1 Clinical | Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd | Small Cell Lung Carcinoma | Details |
| DLL3-CAR-NK cells Therapy(Tianjin Medical University Cancer Institute and Hospital) | DLL3-CAR-NK cells | Phase 1 Clinical | Tianjin Medical University Cancer Institute And Hospital | Small Cell Lung Carcinoma | Details |
| QLS-31904 | QLS31904; QLS-31904 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| LB-2102(Legend Biotechnology) | LB-2102 | Phase 1 Clinical | Small Cell Lung Carcinoma; Neuroendocrine Tumors | Details | |
| PT-217 | PT-217 | Phase 1 Clinical | Phanes Therapeutics Inc | Solid tumours; Small Cell Lung Carcinoma; Pancreatic neuroendocrine tumors (pNET); Prostatic Neoplasms; Carcinoma, Neuroendocrine | Details |
This web search service is supported by Google Inc.
A-Z
